So its pretty likely that theres not going to be a real effect on these other modalities, at least in the initial treatment phase. Dasgupta hopes to see GLP-1s used alongside current treatments, like CPAP
This hypothesis is strongly supported by a consistent body of evidence from large-scale retrospective clinical studies
The results of such studies, including those of large sample size using national cohort data, is still conflicting
Because even as branded drugs become more available and potentially cheaper, the same coverage restrictions, BMI cutoffs, and off-label barriers remain
The GLP-1 receptor is involved in regulating blood sugar levels, while the GIP receptor is involved in stimulating insulin secretion and reducing appetite
Metformin improves insulin sensitivity and liver function, producing modest indirect weight loss